These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23959304)

  • 1. In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Wildum S; Paulsen D; Thede K; Ruebsamen-Schaeff H; Zimmermann H
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5320-9. PubMed ID: 23959304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
    Corbau R; Mori J; Phillips C; Fishburn L; Martin A; Mowbray C; Panton W; Smith-Burchnell C; Thornberry A; Ringrose H; Knöchel T; Irving S; Westby M; Wood A; Perros M
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4451-63. PubMed ID: 20660667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
    J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
    Lai MT; Feng M; Falgueyret JP; Tawa P; Witmer M; DiStefano D; Li Y; Burch J; Sachs N; Lu M; Cauchon E; Campeau LC; Grobler J; Yan Y; Ducharme Y; Côté B; Asante-Appiah E; Hazuda DJ; Miller MD
    Antimicrob Agents Chemother; 2014; 58(3):1652-63. PubMed ID: 24379202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
    Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
    Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
    Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
    Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.